“Oral” describes a route, not one interchangeable product
A swallowed tablet, a drop and a lozenge can all be marketed as avoiding injections, but that shared convenience does not establish equivalent treatment. The active ingredient, formulation and method of administration remain important. Start by writing the exact product name rather than comparing offers under a single heading of oral GLP-1. A route label is too broad to carry a claim about efficacy or safety.
Approved tablets include distinct medicines
Wegovy has approved oral semaglutide tablets as well as an injectable formulation. A compounded semaglutide drop does not acquire the tablet’s approval or supporting evidence simply by sharing the ingredient name. Foundayo is another approved oral option, with the different ingredient orforglipron. Compare the exact medicine and formulation: “oral GLP-1” is not one interchangeable product, and approval does not extend to compounded preparations.[3]
A clinical trial tests more than an ingredient name
Researchers study a specified intervention under a defined protocol. Changing the formulation can change the question being asked, so a trial citation beside a different product does not establish that the new product performs the same way. Ask whether the exact preparation was studied and what outcome was measured. If the answer names only the ingredient, the equivalence question remains unanswered. Related reading: how to read GLP-1 research.
Ask what happens to the medicine after administration
For a proposed oral product, ask the pharmacist to explain the formulation and the evidence supporting its intended use. Do not assume that placing a product under the tongue is equivalent to swallowing a studied tablet, or that an injection study answers the same question. The relevant issue is evidence for the actual preparation, not which route sounds more sophisticated or convenient.
Do not use price to erase product status
A lower advertised payment can be useful commercial information, but it cannot establish therapeutic equivalence. Keep the product category next to the price, and identify what the payment includes. Comparing an approved medication with an unapproved preparation as though the only difference is cost leaves out a central part of the decision. The prescriber should explain why the offered option is appropriate for the patient.[2]
A pharmacy question should have a specific answer
Ask for the dispensing pharmacy, complete ingredient information, instructions and the reason a compounded preparation is being considered. FDA says compounded drugs should be used when an approved drug cannot meet a patient’s medical need. A generic answer that a preparation is “custom” does not tell the patient what need is being addressed. Request that explanation in the clinical conversation.[2]
Watch for evidence that changes products mid-sentence
A promotion may introduce an approved tablet, cite its trial and then invite readers to buy a different oral preparation. Read each step carefully. Check that the medicine in the citation is the medicine in the offer. If they differ, ask for evidence supporting the offered preparation instead of assuming the first product’s results transfer automatically. Related reading: Foundayo approval evidence.
Build a comparison around verifiable details
Use separate fields for active ingredient, dosage form, approval status, supporting study and total cost. Leave a field unanswered if the service cannot document it. This simple structure makes differences visible without requiring a consumer to infer pharmacology from marketing. It also gives the clinician a concrete set of questions to address before a purchase is made.
Continue your research
Sources & scope
Sources checked October 13, 2026. This guide explains published information and consumer research questions; it is not a clinical evaluation.
- FDA: Foundayo prescribing information
- FDA: concerns about unapproved GLP-1 drugs
- Wegovy prescribing information: tablets and injection
Prices and terms can change. Confirm your specific offer directly with the provider.